VIP/VPAC Receptor Modulators for Neurodegeneration

📖 Wiki Page

therapeutic725 wordssynced 2026-04-02

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

flowchart TD VIP_VPAC_Receptor_Modulators_f["VIP/VPAC Receptor Modulators for Neurodegenerati"] VIP_VPAC_Receptor_Modulators_f["table"] VIP_VPAC_Receptor_Modulators_f -->|"related to"| VIP_VPAC_Receptor_Modulators_f style VIP_VPAC_Receptor_Modulators_f fill:#81c784,stroke:#333,color:#000 VIP_VPAC_Receptor_Modulators_f["class"] VIP_VPAC_Receptor_Modulators_f -->|"related to"| VIP_VPAC_Receptor_Modulators_f style VIP_VPAC_Receptor_Modulators_f fill:#81c784,stroke:#333,color:#000 VIP_VPAC_Receptor_Modulators_f["infobox"] VIP_VPAC_Receptor_Modulators_f -->|"related to"| VIP_VPAC_Receptor_Modulators_f style VIP_VPAC_Receptor_Modulators_f fill:#81c784,stroke:#333,color:#000 style VIP_VPAC_Receptor_Modulators_f fill:#4fc3f7,stroke:#333,color:#000

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VIP/VPAC Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Aviptadil (RL-001)</td>
<td>VPAC1/VPAC2</td>
</tr>
<tr>
<td class="label">Ro 25-1392</td>
<td>VPAC2</td>
</tr>
<tr>
<td class="label">BAY 55-9837</td>
<td>VPAC1/VPAC2</td>
</tr>
</table>

...

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

Mermaid diagram (expand to render)

Vasoactive intestinal peptide (VIP) receptor modulators represent a promising therapeutic approach for neurodegenerative diseases. VIP signals through VPAC1 and VPAC2 receptors, G protein-coupled receptors (GPCRs) of the secretin family, to exert neuroprotective, anti-inflammatory, and immunomodulatory effects["@harmar2012"]. This page covers drug candidates, clinical development status, and delivery strategies for VIP-based therapies in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related disorders.

Therapeutic Rationale

Neuroprotective Mechanisms

VIP receptor activation produces multiple neuroprotective effects:

cAMP/PKA/CREB signaling: Promotes expression of neurotrophic factors including BDNF[@gozes2009]
PI3K/Akt pathway: Inhibits GSK-3β, prevents tau phosphorylation, blocks apoptosis
Anti-inflammatory effects: Suppresses NF-κB, shifts microglia to M2 phenotype, reduces pro-inflammatory cytokines
Synaptic plasticity: Enhances LTP, increases dendritic spine density
Mitochondrial protection: Preserves Complex I activity, reduces oxidative stress

Disease-Specific Rationale

Alzheimer's Disease

VIP-based therapies address core AD pathology through multiple mechanisms[@brenneman2003][@pass2006]:

Amyloid modulation: Reduces Aβ-induced neurotoxicity, promotes non-amyloidogenic APP processing
Tau pathology: VIP-activated Akt inhibits GSK-3β, reducing tau phosphorylation
Synaptic dysfunction: Enhances hippocampal plasticity and cognitive function
Neuroinflammation: Suppresses microglial activation and pro-inflammatory cytokine production
Cholinergic protection: Protects basal forebrain cholinergic neurons

Parkinson's Disease

VIP offers dopaminergic neuroprotection through[@offen2000][@samaranch2014][@kong2012]:

Dopaminergic neuron protection: Reduces 6-OHDA and MPTP toxicity
Alpha-synuclein modulation: May reduce aggregation, enhance autophagy clearance
Neuroinflammation: Suppresses microglial activation in substantia nigra
Blood-brain barrier protection: Preserves BBB integrity

Amyotrophic Lateral Sclerosis

VIP provides motor neuron protection in ALS models[@nguyen2001]:

Extends survival in SOD1 mutant mice
Protects against glutamate-induced excitotoxicity
Modulates glial responses
Reduces harmful microglial activation

Huntington's Disease

VIP shows promise in HD models[@maqbool2013]:

Reduces mutant huntingtin (mHTT) aggregation
Counteracts transcriptional dysregulation
Enhances BDNF expression
Improves motor function

Drug Candidates

Peptide Agonists

Aviptadil (RL-001)

Aviptadil is a synthetic 28-amino acid VIP analog that has undergone clinical testing:

Mechanism: Mixed VPAC1/VPAC2 agonist
Clinical experience: Tested in respiratory and inflammatory conditions; safety established in >1,000 subjects
Neurodegeneration potential: Shown to cross the blood-brain barrier in animal models
Current status: Being investigated for repurposing in AD and PD

Delivery Strategies

Challenges

VIP-based therapeutics face significant delivery challenges[@bundgaard2012][@kumar2015]:

Short half-life: VIP circulates with t½ < 2 minutes due to proteolytic degradation
Blood-brain barrier: Limited passive diffusion requires active transport strategies
Receptor desensitization: VPAC receptors internalize with chronic exposure

Approaches

Intranasal delivery: Bypasses the blood-brain barrier for direct nose-to-brain transport
Peptide engineering: D-amino acid substitutions, cyclization for enhanced stability
Gene therapy: AAV-mediated VIP delivery for long-term expression
Focused ultrasound: Temporary BBB opening for enhanced delivery

GLP-1 Receptor Agonists

VIP/VPAC modulators share similarities with GLP-1 receptor agonists:

Both are neuroprotective peptides
Activate cAMP/PKA pathways
Reduce neuroinflammation
Clinical trials ongoing for both

Key differences:

VIP has broader receptor distribution
GLP-1 agonists have better clinical track record
VIP has stronger immunomodulatory effects

Side Effects and Safety

VIP-based therapies have shown favorable safety profiles:

Common: Mild flushing, headache, nausea
Hypotension: Due to VPAC-mediated vasodilation
Hypoglycemia: VPAC1 affects insulin secretion

Contraindications

VIPoma (VIP-producing tumors)
Uncontrolled diabetes
Severe cardiovascular disease

[VIP Signaling Pathway in Neurodegeneration](/mechanisms/vip-vasoactive-intestinal-peptide-signaling-neurodegeneration)
[Vipr1 Protein](/proteins/vipr1-protein)
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
[GLP-1 Receptor Agonists for Neurodegeneration](/therapeutics/glp-1-receptor-agonists-neurodegeneration)

References

[Gozes et al., Vasoactive intestinal peptide: neuroprotective drug? (2009)](https://pubmed.ncbi.nlm.nih.gov/19489073/)

[Harmar et al., VPAC receptors (2012)](https://pubmed.ncbi.nlm.nih.gov/22641679/)

[Mendoza et al., VIP receptor agonists (2010)](https://pubmed.ncbi.nlm.nih.gov/20594243/)

[Brenneman et al., VIP in Alzheimer's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12676047/)

[Offen et al., VIP in Parkinson's disease models (2000)](https://pubmed.ncbi.nlm.nih.gov/10936052/)

[Samaranch et al., VIP and alpha-synuclein (2014)](https://pubmed.ncbi.nlm.nih.gov/24993973/)

[Nguyen et al., VIP in ALS models (2001)](https://pubmed.ncbi.nlm.nih.gov/11331478/)

[Maqbool et al., VIP in Huntington's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24389752/)

[Pass et al., VIP and amyloid (2006)](https://pubmed.ncbi.nlm.nih.gov/16684958/)

[Kong et al., VIP neuroinflammation (2012)](https://pubmed.ncbi.nlm.nih.gov/22935466/)

[Bundgaard et al., Peptide delivery to the brain (2012)](https://pubmed.ncbi.nlm.nih.gov/22653852/)

[Kumar et al., VIP delivery strategies (2015)](https://pubmed.ncbi.nlm.nih.gov/26254873/)

[Cummings et al., Alzheimer's disease drug development pipeline (2024)](https://pubmed.ncbi.nlm.nih.gov/38465234/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

VIP/VPAC Receptor Modulators for Neurodegeneration

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

VIP/VPAC Receptor Modulators for Neurodegeneration

Overview

Therapeutic Rationale

Neuroprotective Mechanisms

Disease-Specific Rationale

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Drug Candidates

Peptide Agonists

Aviptadil (RL-001)

Delivery Strategies

Challenges

Approaches

Comparison with Related Approaches

GLP-1 Receptor Agonists

Side Effects and Safety

Contraindications

Related Pages

References

Related Hypotheses